Erratum: On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: Insights from ROCKET AF (Circulation (2016) 134 (37-47) DOI: 10.1161/CIRCULATIONAHA.116.021890);On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin

Circulation

Volumn 134, Issue 1, 2016, Pages 37-47

  Fordyce, Christopher B ^a   Hellkamp, Anne S ^a   Lokhnygina, Yuliya ^a   Lindner, Samuel M ^a   Piccini, Jonathan P ^a   Becker, Richard C ^b   Berkowitz, Scott D ^c   Breithardt, Günter ^d   Fox, Keith A A ^e   Mahaffey, Kenneth W ^f   Nessel, Christopher C ^g   Singer, Daniel E ^h   Patel, Manesh R ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Janssen Research and Development   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anticoagulants; atrial fibrillation; kidney; renal insufficiency

Indexed keywords

CREATININE; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHAD; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION DETERIORATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME; BLEEDING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; EMBOLISM; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; STROKE; THROMBOPHILIA;

AGED; ATRIAL FIBRILLATION; CREATININE; DOUBLE-BLIND METHOD; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RIVAROXABAN; STROKE; THROMBOPHILIA; WARFARIN;

EID: 84977267659     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000451     Document Type: Erratum

References (32)

1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010 138 1093 1100. doi: 10.1378/chest.10-0134.
2. Vázquez E, Sánchez-Perales C, The HAS-BLED score and renal failure. Chest 2011 139 1248 1249. author reply 1249. doi: 10.1378/chest.10-2961.
3. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE, A new risk scheme to predict warfarin-Associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011 58 395 401. doi: 10.1016/j.jacc.2011.03.031.
4. Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayer WC, Ma Z, Hemmelgarn BR, Alberta Kidney Disease Network The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015 350 h246
5. Johnston JA, Cluxton RJ Jr, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH, Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 2003 163 1705 1710. doi: 10.1001/archinte.163.14.1705.
6. Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC, Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009 54 1280 1289
7. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC, National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012 5 615 621. doi: 10.1161/CIRCOUTCOMES.112.967299.
8. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L, Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis. Circulation 2014 129 961 970. doi: 10.1161/CIRCULATIONAHA.113.003628.
9. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM, Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011 32 2387 2394. doi: 10.1093/eurheartj/ehr342.
10. Pathak R, Pandit A, Karmacharya P, Aryal MR, Ghimire S, Poudel DR, Shamoun FE, Meta-Analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol 2015 115 323 327. doi: 10.1016/j.amjcard.2014.10.042.
11. Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L, Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. J Am Coll Cardiol 2015 65 2481 2493. doi: 10.1016/j.jacc.2015.03.577.
12. Kubitza D, Becka M, Roth A, Mueck W, Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008 24 2757 2765. doi: 10.1185/03007990802361499.
13. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-An oral, direct factor Xa inhibitor-After multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005 61 873 880. doi: 10.1007/s00228-005-0043-5.
14. Diener HC, Halperin JL, Fox K, Hankey GJ, Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation. Int J Clin Pract 2015 69 743 756. doi: 10.1111/ijcp.12631.
15. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H, Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010 70 703 712. doi: 10.1111/j.1365-2125.2010.03753.x.
16. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 365 883 891. doi: 10.1056/NEJMoa1009638.
17. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010 159 340 347.e1
18. Cockcroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 31 41
19. Clark H, Krum H, Hopper I, Worsening renal function during renin-Angiotensin-Aldosterone system inhibitor initiation and long-Term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail 2014 16 41 48. doi: 10.1002/ejhf.13.
20. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-Analysis. Eur Heart J 2014 35 455 469. doi: 10.1093/eurheartj/eht386.
21. Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C, Interaction between baseline and early worsening of renal function and efficacy of renin-Angiotensin-Aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail 2013 15 1236 1244. doi: 10.1093/eurjhf/hft089.
22. Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F, Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012 125 271 279. doi: 10.1161/CIRCULATIONAHA.111.028282.
23. Testani JM, Kimmel SE, Dries DL, Coca SG, Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011 4 685 691. doi: 10.1161/CIRCHEARTFAILURE.111.963256.
24. Testani JM, McCauley BD, Chen J, Shumski M, Shannon RP, Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions. Cardiology 2010 116 206 212. doi: 10.1159/000316038.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 461 470
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 150 604 612
27. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005 3 692 694. doi: 10.1111/j.1538-7836.2005.01204.x.
28. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L, ARISTOTLE Investigators Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010 159 331 339. doi: 10.1016/j.ahj.2009.07.035.
29. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S, Rationale and design of RE-LY: randomized evaluation of long-Term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009 157 805 810, 810.e1. doi: 10.1016/j.ahj.2009.02.005.
30. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKET AF Steering Committee and Investigators Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013 127 224 232. doi: 10.1161/CIRCULATIONAHA.112.107128.
31. Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED, Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 2015 170 141 148.e1
32. US Food and Drug Administration Guidance for Industry: Pharmacokinetics in Patients With Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling 1998 Rockville, MD US Department of Health and Human Services. http://www.fda.gov/downloads/Drugs/./Guidances/UCM204959.pdf. Accessed June 10, 2016.